Cyfuse Biomedical KK

Cyfuse Biomedical KK EBITDA per Employee

The EBITDA per Employee of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is -39.44 M JPY. In the previous year, EBITDA per Employee was -41.94 M JPY — a change of -5.98% (higher).

EBITDA per Employee

-39.44 MJPY

YoY

-5.98%

Last updated:

EBITDA per Employee of Cyfuse Biomedical KK is 2025 -39.44 M JPY. EBITDA per Employee of Cyfuse Biomedical KK was 2024 -41.94 M JPY. It decreases by -5.98% higher compared to the previous year.

The Cyfuse Biomedical KK EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2020
-17.57 M JPY
Jan 1, 2021
3.47 M JPY
Jan 1, 2022
-19.53 M JPY
Jan 1, 2023
-32.74 M JPY
Jan 1, 2024
-41.94 M JPY
Jan 1, 2025
-39.44 M JPY
The Cyfuse Biomedical KK EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-39.44 MJPY-5.98%
-41.94 MJPY+28.11%
-32.74 MJPY+67.64%
-19.53 MJPY-662.06%
3.47 MJPY-119.78%
-17.57 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

EBITDA per Employee of Cyfuse Biomedical KK is -39.44 M JPY in 2025.

EBITDA per Employee of Cyfuse Biomedical KK changed from -41.94 M JPY to -39.44 M JPY, representing a -5.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Cyfuse Biomedical KK historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Cyfuse Biomedical KK

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Cyfuse Biomedical KK